Literature DB >> 29487892

Predicting human clinical trial responses in mice.

Hui Gao1, Juliet Anne Williams1.   

Abstract

Preclinical modeling of human Phase II oncology trials by traditional methods has failed to be highly predictive. Here, we comment on our data showing that much better prediction of clinical trial results can be achieved using a broad-based patient-derived xenograft (PDX) panel.

Entities:  

Keywords:  Clinical relevance; PCT; patient-derived xenograft; reproducibility; translatability

Year:  2018        PMID： 29487892      PMCID： PMC5821416          DOI： 10.1080/23723556.2016.1162895

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

Review 2.  Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology.

Authors:  Edward Rosfjord; Judy Lucas; Gang Li; Hans-Peter Gerber
Journal:  Biochem Pharmacol       Date:  2014-06-17       Impact factor: 5.858

3.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

Authors:  Hui Gao; Joshua M Korn; Stéphane Ferretti; John E Monahan; Youzhen Wang; Mallika Singh; Chao Zhang; Christian Schnell; Guizhi Yang; Yun Zhang; O Alejandro Balbin; Stéphanie Barbe; Hongbo Cai; Fergal Casey; Susmita Chatterjee; Derek Y Chiang; Shannon Chuai; Shawn M Cogan; Scott D Collins; Ernesta Dammassa; Nicolas Ebel; Millicent Embry; John Green; Audrey Kauffmann; Colleen Kowal; Rebecca J Leary; Joseph Lehar; Ying Liang; Alice Loo; Edward Lorenzana; E Robert McDonald; Margaret E McLaughlin; Jason Merkin; Ronald Meyer; Tara L Naylor; Montesa Patawaran; Anupama Reddy; Claudia Röelli; David A Ruddy; Fernando Salangsang; Francesca Santacroce; Angad P Singh; Yan Tang; Walter Tinetto; Sonja Tobler; Roberto Velazquez; Kavitha Venkatesan; Fabian Von Arx; Hui Qin Wang; Zongyao Wang; Marion Wiesmann; Daniel Wyss; Fiona Xu; Hans Bitter; Peter Atadja; Emma Lees; Francesco Hofmann; En Li; Nicholas Keen; Robert Cozens; Michael Rugaard Jensen; Nancy K Pryer; Juliet A Williams; William R Sellers
Journal:  Nat Med       Date:  2015-10-19       Impact factor: 53.440

4.  Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.

Authors:  F M Kaplan; Y Shao; M M Mayberry; A E Aplin
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

5.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

6.  Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.

Authors:  Sara A Flanigan; Todd M Pitts; Timothy P Newton; Gillian N Kulikowski; Aik Choon Tan; Martine C McManus; Anna Spreafico; Maria I Kachaeva; Heather M Selby; John J Tentler; S Gail Eckhardt; Stephen Leong
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

7.  Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Authors:  Miriam Molina-Arcas; David C Hancock; Clare Sheridan; Madhu S Kumar; Julian Downward
Journal:  Cancer Discov       Date:  2013-03-01       Impact factor: 39.397

8.  Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

Authors:  Paolo A Ascierto; David Minor; Antoni Ribas; Celeste Lebbe; Anne O'Hagan; Niki Arya; Mary Guckert; Dirk Schadendorf; Richard F Kefford; Jean-Jacques Grob; Omid Hamid; Ravi Amaravadi; Ester Simeone; Tabea Wilhelm; Kevin B Kim; Georgina V Long; Anne-Marie Martin; Jolly Mazumdar; Vicki L Goodman; Uwe Trefzer
Journal:  J Clin Oncol       Date:  2013-08-05       Impact factor: 44.544

9.  Clinical approval success rates for investigational cancer drugs.

Authors:  J A DiMasi; J M Reichert; L Feldman; A Malins
Journal:  Clin Pharmacol Ther       Date:  2013-06-05       Impact factor: 6.875

Review 10.  Patient-derived xenograft models: an emerging platform for translational cancer research.

Authors:  Manuel Hidalgo; Frederic Amant; Andrew V Biankin; Eva Budinská; Annette T Byrne; Carlos Caldas; Robert B Clarke; Steven de Jong; Jos Jonkers; Gunhild Mari Mælandsmo; Sergio Roman-Roman; Joan Seoane; Livio Trusolino; Alberto Villanueva
Journal:  Cancer Discov       Date:  2014-07-15       Impact factor: 39.397
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.